BIOMAT Database Logo BIOMAT Database Logo

The arginine-vasopressin secretion profile of children with primary nocturnal enuresis. 1998

T Aikawa, and T Kasahara, and M Uchiyama
Department of Pediatrics, Niigata Prefectural Kamo Hospital, Japan. tsutomun@alles.or.jp

OBJECTIVE The aim of this group of studies was to determine the relationship between primary nocturnal enuresis and arginine-vasopressin (AVP) secretion. METHODS The first study compared the 24-hour AVP secretion profiles of an enuretic group and a control group. Blood samples were collected every hour. In the second study, we compared nocturnal AVP secretion in group A, with low urinary osmotic pressure (UOP) and large nocturnal urinary volume (NUV), with that of group D, with normal UOP and small NUV. The plasma AVP level was measured at 30-min sampling intervals. In the third study, the change in nocturnal AVP secretion from before to after treatment was determined. RESULTS The plasma AVP level was significantly lower in the enuretic group from 23:00 through 04:00 h. The mean plasma AVP level was significantly lower in group A than in group D at all points of measurement. The mean nocturnal AVP level in group A (0.64 +/- 0.23 pg/ml) was lower than that in group D (1.43 +/- 0.72 pg/ml) (p < 0.0001). The mean nocturnal AVP level after treatment was significantly increased, from 0.47 pg/ml before treatment to 0.78 pg/ml after treatment (p = 0.01). However, a significant increase was noted in only 10 cases. CONCLUSIONS These findings suggest that decreased nocturnal AVP secretion is one of the causes of bed-wetting. However, the improvement of bed-wetting was not solely due to the increased nocturnal AVP secretion.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D004775 Enuresis Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytime (DIURNAL ENURESIS) while one is awake or during sleep (NOCTURNAL ENURESIS). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis).
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit
D014556 Urine Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.

Related Publications

T Aikawa, and T Kasahara, and M Uchiyama
Nocturnal enuresis in children: The role of arginine-vasopressin.
January 2021, Handbook of clinical neurology,
T Aikawa, and T Kasahara, and M Uchiyama
Desamino-D-arginine vasopressin in childhood nocturnal enuresis.
January 1985, The Journal of urology,
T Aikawa, and T Kasahara, and M Uchiyama
Nocturnal polyuria and nocturnal arginine vasopressin (AVP): a key factor in the pathophysiology of monosymptomatic nocturnal enuresis.
January 2009, Neurourology and urodynamics,
T Aikawa, and T Kasahara, and M Uchiyama
The nasal mucosa of children with nocturnal enuresis before and after treatment with 1-deamino 8-D-arginine vasopressin spray.
May 2001, International journal of pediatric otorhinolaryngology,
T Aikawa, and T Kasahara, and M Uchiyama
Subcutaneous vasopressin in nocturnal enuresis.
December 1989, British journal of urology,
T Aikawa, and T Kasahara, and M Uchiyama
Nocturnal enuresis among primary school children.
November 2013, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
T Aikawa, and T Kasahara, and M Uchiyama
Brainstem evaluation in children with primary nocturnal enuresis.
February 2004, Acta medica Okayama,
T Aikawa, and T Kasahara, and M Uchiyama
Primary nocturnal enuresis in children with vesicoureteric reflux.
March 1987, British medical journal (Clinical research ed.),
T Aikawa, and T Kasahara, and M Uchiyama
Plasma vasopressin and response to treatment in primary nocturnal enuresis.
May 1999, Archives of disease in childhood,
T Aikawa, and T Kasahara, and M Uchiyama
Management of nocturnal enuresis with a vasopressin analogue.
May 1984, The Journal of urology,
Copied contents to your clipboard!